Testa Combo detector 1

TESTA Analytical’s new dual detector boosts performance of demanding GPC/SEC applications

The COMBO-ONE Viscometer/DRI detector from TESTA Analytical sets a new standard for demanding GPC/SEC applications, such as those focused on investigating the structure and branching of polymers.

Integra MIRO CANVAS

Integra’s new MIRO CANVAS significantly simplifies NGS sample preparation

INTEGRA Biosciences has launched MIRO CANVAS, a compact digital microfluidics platform for fully automated next generation sequencing (NGS) sample preparation. The revolutionary system significantly simplifies NGS workflows for more walk-away time and higher lab productivity.

Sartorius Prof Dr Oscar Werner Reif 06

Sartorius partners with SPARTA Biodiscovery to facilitate launch of novel nanoparticle analysis platform

The life science group Sartorius and UK-based start-up SPARTA Biodiscovery have agreed to partner on SPARTA’s analysis platform, which helps speed up the development, manufacture, and quality control of nanoparticles for bio-pharmaceutical drugs.

Aviti system

Revvity, Element Biosciences collaborate to offer more efficient genomic analysis

Revvity and Element Biosciences, the developer of the AVITI System [1], a genomic sequencing platform, will collaborate to introduce workflow solutions that are more efficient for genomic analysis of samples.

shutterstock 1046242816

Emmes acquires VaxTRIALS

Rockville, Maryland, US-based Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, has acquired VaxTRIALS. Headquartered in Panama City, Panama, VaxTRIALS’ 160+ staff members manage and monitor vaccine clinical trial activities throughout Latin America.

Schermafbeelding 2023 10 25 om 17.39.16

Biosynth extends its offering to multi- kilogramme GMP peptide synthesis with acquisition of Pepceuticals

Biosynth, a supplier of critical materials to the life science industry, has acquired Pepceuticals, a UK producer of synthetic peptides with multi-kilogramme GMP facilities and fill-finish capabilities designed to support customers from clinical trials to commercial supply.

Miquel Vila Perello

SpliceBio collaborates with Spark Therapeutics to develop a gene therapy targeting an undisclosed inherited retinal disease

SpliceBio, a Barcelona, Spain-based genetic medicines company harnessing protein splicing to develop the next generation of gene therapies, has signed an exclusive collaboration and licensing agreement with Philadelphia, Pennsylvania-based Spark Therapeutics to utilize SpliceBio’s proprietary protein splicing platform to develop a gene therapy for an undisclosed inherited retinal disease.

shutterstock 1701967852

Gilead and Assembly Biosciences partner to develop next-gen therapeutics

Gilead Sciences has entered into a 12-year partnership with Assembly Biosciences, a biotechnology company developing antiviral therapeutics targeting serious viral diseases. The partnership, announced 17 October, aims to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D […]

shutterstock 2208795407

Mogrify raises $46m to advance reprogramming therapies

Mogrify, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, has closed an additional US$10 million of its Series A financing, bringing the total raised to $46 million in this round. The funding will support further advancement of Mogrify’s pipeline of in vivo reprogramming therapies through pre-clinical […]

shutterstock 2169753685

Yamaha Motor sets up new company to better analyse antibodies in blood

Yamaha Motor Co., Ltd. has established Tuning Fork Bio Inc. in Delaware, USA, which will analyze the antibodies in blood to better visualize people’s health conditions through its antibody profiling business. The main target markets for this new company are the U.S. and Japan.